skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

もっと見る

Resources

もっと見る

もっと見る

Products

もっと見る

もっと見る

31 Total results for product and free and sample content found

世界の薬事規制動向&情報を配信

Pink Sheet – US Election and New Administration Coverage

Stay informed of the latest news from the recent US election and understand how the shift in power will affect pharma regulatory and policy issues both within the United States and abroad. Pink Sheet takes you behind the US election headlines for analysis on the real impact you can expect to see on your business.

Topic us-election-2020

Medtech Insight: 世界の医療機器・医療技術の最新情報

10 Predictions On How Health Policy Could Change Under A Biden Presidency

medtech telehealth joe biden

Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.

Topic US Election 2020 Leadership Policy & Regulation

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

US Drug Pricing Reform Post-Election: Scenarios To Consider And Lessons Learned

Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.

Topic us-election-2020 policy-and-regulation drug-pricing

Medtech Insight: 世界の医療機器・医療技術の最新情報

US Election 2020: Industry Loses Three Favored Incumbents In Battle For Senate Control

A few of the US Senate candidates favored and given tens of thousands of dollars by industry have lost their battles for re-election

Topic us-election-2020 Legislation

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly

A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry

Topic us-election-2020 drug-pricing

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

China-US Relationship Hinges On Changing Internal, External Forces

Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.

Topic US Election 2020 China

Medtech Insight: 世界の医療機器・医療技術の最新情報

US Election 2020: Almost All House Members Backed By Industry PAC Dollars Retain Seats

Out of 31 US House incumbents supported by high amounts of medtech industry political action committee (PAC) dollars, only one – Chrissy Houlahan of Pennsylvania – lost in last week’s election.

Topic us-election-2020 policy-and-regulation Legislation

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Biden's COVID-19 Advisory Board Bodes Well For Science-Driven FDA

Two prominent former US FDA officials are a part of the president-elect’s new COVID-19 advisory board. Biden’s emphasis on scientific independence, including a commitment to publicly release vaccine trial data, could help restore public confidence in the agency and coming COVID-19 vaccines.

Topic us-election-2020 Coronavirus fda

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Biden, Germany And Bringing A National Drug Pricing Negotiation Process To US

Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.

Topic US Election 2020 Drug Pricing

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。